The Vice-President,General Counsel of ImmunoGen (NASDAQ: IMGN) is Buying SharesBy Carrie Williams
This recent transaction increases Craig Barrows’ holding in the company by 47.39% to a total of $34.82K. In addition to Craig Barrows, 3 other IMGN executives reported Buy trades in the last month.
The company has a one year high of $14.22 and a one year low of $1.51. Currently, ImmunoGen has an average volume of 1.67M.
Based on 5 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $5.50, reflecting a -69.8% downside. 10 different firms, including BTIG and Canaccord Genuity, currently also have a Buy rating on the stock.
The insider sentiment on ImmunoGen has been positive according to 17 insider trades in the past three months. This sentiment is slightly higher than the average sentiment of company insiders in this sector.
ImmunoGen, Inc. is a biotechnology company, which develops novel anticancer therapeutics using its antibody-drug conjugate technology. It also have developed engineered linkers that keep the payload firmly attached to the antibody while the whole therapy is circulating through the bloodstream and then release it once the therapy has reached and entered a cancer cell. Its also uses antibody-drug conjugate targeted antibody payload technology together with strong antibody expertise to develop its own product candidates. The company was founded in March 1981 and is headquartered in Waltham, MA.